本报记者 桂小笋 在很多消费者心里，老字号、化学制药等词汇，自带距离感。力生制药党委书记、董事长张平在与《证 券日报》记者交流时表示，希望通过文化叙事，让更多人在想到力生制药时嘴角上扬，"觉得我们是柔 和的、松弛的，大家能一起'玩'起来。" 11月24日，位于天津市河西区平山道43号的实验剧场迎来了一场特殊的"实验"，天津力生制药股份有限 公司（以下简称"力生制药"）与天津北方演艺集团有限公司演艺传媒分公司联合出品的网络短剧在这里 举行了首映仪式。 长期以来，如何让老字号摆脱"老气"、焕发新活力，始终是行业与消费者关注的焦点。在张平看来，解 题的关键，就藏在文化和创新这两个关键词里。 "天津企业的文化是津派文化的重要组成部分，力生制药旗下'三鱼'中华老字号品牌与'寿比山'拳头品 牌，承载了几代人的记忆。"张平向《证券日报》记者介绍，企业选择网络短剧这一轻量化、高传播度 的形式，并非跟风之举，而是希望传递"做好人，做好药"的企业价值观，以老字号企业的正能量引发受 众情感共鸣，实现"文化传情、健康入心"，进而在年轻群体中完成品牌认知升级与影响力破圈。 "文化看不见摸不着，但在关键时刻却能有大用。"张平表示，要让文 ...

本报记者 桂小笋 11月24日，位于天津市河西区平山道43号的实验剧场迎来了一场特殊的"实验"，天津力生制药股份有限 公司（以下简称"力生制药"）与天津北方演艺集团有限公司演艺传媒分公司联合出品的网络短剧在这里 举行了首映仪式。 "情绪价值与情绪消费对企业发展至关重要，为了找对方向，我们做了大量的功课。不仅研读相关学术 著作，寻找理论支撑，还安排党群工作部系统研究流行叙事的理论逻辑、市场基础与推广手法。"张平 告诉《证券日报》记者，经过反复论证，力生制药提出"以文化叙事促进中华老字号品牌传播"的课题。 对于合作的作品，张平表示，力生制药更关注长期文化影响力，而非短期传播热度与广告曝光效果。 在很多消费者心里，老字号、化学制药等词汇，自带距离感。力生制药党委书记、董事长张平在与《证 券日报》记者交流时表示，希望通过文化叙事，让更多人在想到力生制药时嘴角上扬，"觉得我们是柔 和的、松弛的，大家能一起'玩'起来。" 在文化叙事的整体规划方面，张平坦言，力生制药在企业文化建设层面有清晰方案，对外传播明确"以 文化趋势为核心、围绕既定课题推进"的方向，未来仍有许多版图待补齐。他透露，目前，力生制药正 与多家机构探讨合作 ...

格隆汇11月21日｜力生制药(002393.SZ)低开低走，一度跌4.23%至20.16元，股价创7月15日以来逾4个月新低。力生制药公告，公司副总经理郭晓燕拟自公告 披露15个交易日后3个月内以集中竞价方式减持不超11200股，占剔除回购后总股本0.0044%，股份来源为2022年限制性股票激励计划授予股份。(格隆汇) ...

Core Insights - On November 20, several companies disclosed their share repurchase and reduction plans, indicating varying levels of confidence in their stock performance [1] Group 1: Share Repurchase Plans - Eddie Precision plans to repurchase A-shares worth between 100 million to 200 million yuan [2] - Aviation Materials plans to repurchase shares worth between 50 million to 100 million yuan [2] - Changshu Bank's executives plan to increase their holdings by no less than 550,000 shares [2] Group 2: Share Reduction Plans - New Hongze's major shareholder reduced their holdings during a period of abnormal stock fluctuations [2] - General Electric's Singapore company plans to reduce its holdings by no more than 3% in China Xidian [2] - Senior management of Lifespring Pharmaceutical plans to reduce their holdings by no more than 0.0044% [2] - Shareholder Zhoushan Ruihao of Wan Feng plans to reduce holdings by no more than 1.75% [2] - Shareholders of Dongxin plan to collectively reduce holdings by no more than 0.71% [2] - Haigang Group, a shareholder of Hainan Mining, plans to reduce holdings by no more than 0.75% [2] - Actual controller Zhang Guifeng of Fulongma reduced 3.7812 million shares from November 19 to November 20 [2] - Shareholder Dongguan Kechuang Investment Group of Shengyi Electronics plans to reduce holdings by no more than 1% [2] - Shareholder Qinyi Partnership of Yayi Technology plans to reduce holdings by no more than 0.25% [2] - Controlling shareholder Yuansi Industrial of New City plans to reduce holdings by no more than 3% [2] - Controlling shareholder of Kaishan plans to reduce holdings by no more than 1% [2] - The largest shareholder of Tuo Jing Technology, the National Fund, plans to reduce holdings by no more than 3% [2] - Controlling shareholder Li Zheng of Wajinjiao plans to reduce holdings by no more than 3% [2] - Shareholder Shanxi Huaxin Hai of Baose plans to reduce holdings by no more than 1% [2] - Shareholders of Huaya Intelligent plan to collectively reduce holdings by 399.21 million shares, accounting for 2.98% of total share capital [2] - Directors and executives of Changxin Bochuang plan to collectively reduce holdings by no more than 0.05% [2] - Shareholders of Longxun plan to collectively reduce holdings by no more than 2.63% [2] - Some directors and executives of Fulede plan to collectively reduce holdings by no more than 0.0104% [2]

Core Points - The company, Lisheng Pharmaceutical, announced that senior management personnel, Guo Xiaoyan, plans to reduce her holdings in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [2] Summary by Category Company Announcement - Guo Xiaoyan holds 114,800 shares, representing 0.0446% of the company's total share capital and 0.0448% of the total share capital excluding shares in the repurchase account [2] - The planned reduction in shareholding will not exceed 0.0044% of the total share capital after excluding shares in the repurchase account [2]

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that senior management personnel Guo Xiaoyan plans to reduce holdings of the company's shares through centralized bidding, with a total reduction not exceeding 11,200 shares, which represents a maximum reduction of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1] Summary by Category - **Company Announcement** - Lisheng Pharmaceutical disclosed that Guo Xiaoyan intends to reduce her shareholding in the company [1] - The planned reduction is limited to a total of 11,200 shares [1] - The reduction accounts for a maximum of 0.0044% of the total share capital after excluding repurchased shares [1]

Core Viewpoint - The company, Lisheng Pharmaceutical (002393.SZ), announced that senior management personnel, Guo Xiaoyan, plans to reduce her shareholding in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [1] Summary by Categories Shareholding Reduction Plan - Guo Xiaoyan holds 114,800 shares in the company and intends to sell no more than 11,200 shares [1] - The planned reduction represents a maximum of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1]

Group 1 - Company Lifesun Pharmaceutical (SZ 002393) announced that senior management personnel Guo Xiaoyan plans to reduce her holdings by no more than approximately 11,200 shares within three months after 15 trading days from the announcement date, representing a maximum reduction of 0.0044% of the total share capital excluding shares in the repurchase account [1] - As of the report date, Lifesun Pharmaceutical's market capitalization is 5.4 billion yuan [1] - For the first half of 2025, the revenue composition of Lifesun Pharmaceutical is 100% from the pharmaceutical industry [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-075 天津力生制药股份有限公司 关于公司高级管理人员减持股份预披露公告 本公司高级管理人员郭晓燕女士保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有天津力生制药股份有限公司（以下简称"公司"）114,800股（占公司总股本比例 0.0446%；占公司剔除回购专用账户中股份数量后的总股本比例0.0448%）的公司高级管 理人员郭晓燕女士，计划在本公告披露之日起15个交易日后的3个月内以集中竞价方式减持 本公司股份合计不超过11,200股，拟减持股份比例不超过公司剔除回购专用账户中股份数 量后总股本的0.0044%。 公司于近日收到高级管理人员郭晓燕女士出具的《股份减持计划申请表》，现将具体 内容公告如下： | 一、拟减持股东的基本情况 | | --- | | | 担任职务 | 持股数量（股） | 占公司总股本 | 占公司剔除回购 专用账户股份数 | 其中持有无限售 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that its Vice President, Guo Xiaoyan, holds 114,800 shares, accounting for 0.0446% of the total share capital, and plans to reduce holdings by up to 11,200 shares within three months after the announcement [1] Summary by Categories Shareholding Information - Guo Xiaoyan's current shareholding is 114,800 shares, which represents 0.0446% of the total share capital [1] - After excluding repurchased shares, the shareholding percentage is 0.0448% [1] Reduction Plan - The planned reduction involves selling up to 11,200 shares, which constitutes 0.0044% of the total share capital after excluding repurchased shares [1] - The shares to be sold are sourced from the 2022 restricted stock incentive plan [1]